As filed with the Securities and Exchange Commission on February 12, 2009
 Registration No. 333-83724
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST-EFFECTIVE AMENDMENT NO. 2 TO
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
NOVO NORDISK A/S
(Exact name of registrant as specified in its charter)
 
Kingdom of Denmark
  
None
(State or other jurisdiction of incorporation
or organization)
  
(I.R.S. Employer
Identification No.)
 
Novo Allé
DK-2880 Bagsvaerd
Denmark
Tel. No.: (45) 44-44-88-88
  
(Address, including zip code, and telephone number including area code, of registrant’s principal executive offices)
 
NOVO NORDISK, INC. 401(k) SAVINGS PLAN
(f/k/a NOVO NORDISK PHARMACEUTICALS, INC. 401(k) SAVINGS PLAN)
NOVO NORDISK PUERTO RICO 401(k) PLAN
(Full title of plan)
 
James C. Shehan, Esq.
General Counsel
Novo Nordisk Inc.
100 College West
Princeton, New Jersey 08540
Tel. No.: (609) 987-5800
Fax No.: (609) 919-7741
  
(Name, address, including  zip code, and telephone number, including area code, of agent for service)
Copies to:
Jean McLoughlin, Esq.
Davis Polk & Wardwell
450 Lexington Avenue
New York, New York  10017
Tel. No.: (212) 450-4000
 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer    x
Accelerated filer    o
   
Non-accelerated filer   o  (Do not check if a smaller reporting company)
Smaller reporting company    o

 
 

 
 

EXPLANATORY NOTE
 
Novo Nordisk A/S, a Denmark corporation (“Novo Nordisk”, “Company” or “Registrant”), hereby amends its Registration Statement on Form S-8 File No. 333-83724, by filing this Post-Effective Amendment No. 2 on Form S-8 relating to 1,000,000 B Shares, which is represented by one American Depositary Share of the Company and the indeterminate amount of interests that are issuable by the Company pursuant to the Novo Nordisk, Inc. 401(k) Savings Plan (f/k/a Novo Nordisk Pharmaceuticals, Inc. 401(k) Savings Plan) and the Novo Nordisk Puerto Rico 401(k) Plan.  This Post-Effective amendment No. 2 to our Registration Statement filed on Form S-8 is filed solely for the purpose of providing the consent of PricewaterhouseCoopers LLP, independent registered public accounting firm of the Company, to the incorporation by reference in the Registration Statement on Form S-8 of its report dated 28 January 2009 relating to the Consolidated Financial Statements and the effectiveness of internal control over financial reporting, which appears in the Form 20-F filed by Novo Nordisk on February 9, 2009.
 
ITEM 8. Exhibits
 
 
Exhibit No.
  
 
Description
4.1*
  
Novo Nordisk, Inc. 401(k) Savings Plan, as amended (f/k/a Novo Nordisk Pharmaceuticals, Inc. 401(k) Savings Plan)
     
4.5*
  
Deposit Agreement, dated February 1, 1981 amended September 10, 1984, amended and restated May 1, 1991, amended April 15, 1994, December 21, 1996, and April 4, 2004, among Novo Nordisk, Morgan Guaranty Trust Company of New York and holders of American Depositary Receipts
     
4.6*
  
Novo Nordisk Puerto Rico 401(k) Plan
     
23.1*
  
Consent of PricewaterhouseCoopers LLP
     
23.2*
  
Consent of Amper, Poliztiner & Mattia, LLP (formerly Amper, Politziner & Mattia, P.C.)
     
23.3
  
Consent of PricewaterhouseCoopers LLP
     
24*
  
Power of Attorney
 
*Previously filed
 
 
2
 
SIGNATURES
 
The Registrant. Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8, and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Princeton, New Jersey, on the 12th day of February, 2009.
 
NOVO NORDISK A/S
  
   
   
By:
*
  
 
Lars Rebien Sørensen
  
 
President and Chief Executive Officer
  

 
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by or on behalf of the following persons in the capacities and on the dates indicated.
 
Signature
  
Title
  
Date
         
*
  
President & Chief Executive Officer
  
February 12, 2009
Lars Rebien Sørensen
        
         
*
  
Chief Financial Officer
  
February 12, 2009
Jesper Brandgaard
        
         
*
  
Chairman of the Board of Directors
   February 12, 2009
Sten Scheibye
      
 
         
*
  
Vice Chairman of the Board of Directors
  
February 12, 2009
Göran A. Ando
        
         
*
  
Director
  
February 12, 2009
Kurt Briner
        
         
*
  
Director
  
February 12, 2009
Henrik Gürtler
        
         
*
  
Director
  
February 12, 2009
Johnny Henriksen
        
         
*
  
Director
  
February 12, 2009
Pamela J. Kirby
        
         
 
 
3
 
*
  
Director
  
February 12, 2009
Anne Marie Kverneland
        
         
*
  
Director
  
February 12, 2009
Kurt Anker Nielsen
        
         
*
  
Director
  
February 12, 2009
Stig Strøbæk
        
         
*
  
Director
  
February 12, 2009
Jørgen Wedel
        
         
*
  
Director
  
February 12, 2009
Søren Thuesen Pedersen
        
 
 
 
4
 
AUTHORIZED REPRESENTATIVE
 
 
/s/ James C. Shehan
James C. Shehan
as the duly authorized representative
of Novo Nordisk A/S in the United States
 
Date:  February 12, 2009
 
 

 
5

 *By: 
  /s/ James C. Shehan
James C. Shehan
Attorney-in-Fact
   
Date:  February 12, 2009

 

 
6
 

 
 
EXHIBIT INDEX
 
 
Exhibit No.
  
 
Description
4.1*
  
Novo Nordisk, Inc. 401(k) Savings Plan, as amended (f/k/a Novo Nordisk Pharmaceuticals, Inc. 401(k) Savings Plan)
     
4.5*
  
Deposit Agreement, dated February 1, 1981 amended September 10, 1984, amended and restated May 1, 1991, amended April 15, 1994, December 21, 1996, and April 4, 2004, among Novo Nordisk, Morgan Guaranty Trust Company of New York and holders of American Depositary Receipts
     
4.6*
  
Novo Nordisk Puerto Rico 401(k) Plan
     
23.1*
  
Consent of PricewaterhouseCoopers LLP
     
23.2*
  
Consent of Amper, Poliztiner & Mattia, LLP (formerly Amper, Politziner & Mattia, P.C.)
     
23.3
  
Consent of PricewaterhouseCoopers LLP
     
24*
  
Power of Attorney
 
 
*Previously filed
 
 
 
7